Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Names Alport Syndrome as Next Pipeline Indication

Premium

Regulus Therapeutics this week announced that has formally added its preclinical program in the rare kidney disease Alport syndrome to its drug-development pipeline — a move widely expected based on company comments and recently released animal data linking microRNA-21 to the disease.

Alport syndrome is caused by mutations in three genes that affect production of the type IV collagen family of proteins. The result is a disruption to the structure of the glomerular basement membrane, increased expression of miR-21, an increase in fibrosis, and the loss of renal function, which ultimately leads to end-stage renal disease, according to the company.

Late last year, Regulus announced that in a mouse model of Alport syndrome, inhibiting miR-21 "significantly decreased the rate of decline of renal fibrosis, restored the expression of key microRNAs involved in maintaining renal function, and increased the lifespan of the mice by 20 percent to 50 percent depending upon the genetic background of the collagen 4A3 mutation."

At the time, company officials also indicated that the disease would likely form the foundation of its next drug candidate, which has now been dubbed RD-012.

"This program underscores Regulus' focus on orphan disease indications, and we look forward to rapidly advancing and expanding our clinical portfolio of meaningful microRNA therapeutics," Regulus President and CEO Kleanthis Xanthopoulos said in a statement.

As reported by Gene Silencing News earlier this month, the Alport syndrome program is covered by Regulus' recently restructured alliance with Sanofi, which has the right to take over RG-012's development after Regulus has established clinical proof of concept.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.